[Investigation of possible approaches to angiogenesis regulation in vitro with the help of recombinant fragments of angiogenesis inhibitors such as endostatin, tumstatin and PEDF]

Vestn Ross Akad Med Nauk. 2013:(4):63-7. doi: 10.15690/vramn.v68i4.613.
[Article in Russian]

Abstract

Neovascular diseases of visual organ such as age-related macular degeneration, retinopathy of prematurity, diabetic retinopathy, thrombosis of central retina vein and its branches, neovascular glaucoma, choroid and retina tumors have the leading positions in the list of ophtalmopatologies that result in blindness and incapacity. The variety of angiostatic medications of applied ophtalmology is scant. The aim of work was to study the possibile approaches to angiogenesis regulation in vitro with the help of recombinant fragments of natural inhibitors of angiogenesis such as endostatin, tumstatin and PEDF (pigment epithelial derived factor), and also theirability to be the base of potentially feasible and pharmacologically active substances. It is determined that endostatin, tumstatin and PEDF, as well as the comparison medication Bevacizumab in vitro have pro-or antiangiogenic influence. The direction of the biological effect depends on the cultivation conditions, peptide concentration in the cultural fluid and stage of angiogenesis.

Publication types

  • Comparative Study
  • English Abstract

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Autoantigens / therapeutic use*
  • Cells, Cultured
  • Choroidal Neovascularization / drug therapy*
  • Choroidal Neovascularization / pathology
  • Collagen Type IV / therapeutic use*
  • Diabetic Retinopathy / drug therapy*
  • Diabetic Retinopathy / pathology
  • Endostatins / therapeutic use*
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / pathology
  • Epitopes
  • Eye Proteins / therapeutic use*
  • Humans
  • Macular Degeneration / drug therapy*
  • Nerve Growth Factors / therapeutic use*
  • Protease Inhibitors / therapeutic use
  • Recombinant Proteins / therapeutic use
  • Serpins / therapeutic use*
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Autoantigens
  • Collagen Type IV
  • Endostatins
  • Epitopes
  • Eye Proteins
  • Nerve Growth Factors
  • Protease Inhibitors
  • Recombinant Proteins
  • Serpins
  • pigment epithelium-derived factor
  • type IV collagen alpha3 chain